

# THEMIS MEDICARE LTD

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat.  
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

PART I (₹ In Lakhs)

Statement of Audited Financial Results for the year ended 31st March 2013.


Particulars	STANDALONE				CONSOLIDATED		
	Quarter ended			Current year ended	Previous year ended	Current year ended	Previous year ended
	(31/03/2013)	(31/12/2012)	(31/03/2012)	(31/03/2013)	(31/03/2012)	(31/03/2013)	(31/03/2012)
(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1 Income from operations							
(a) Net sales/income from operations (Net of excise duty)	2,298.90	3,435.64	3,418.29	14,393.30	13,485.68	16,825.15	15,317.00
(b) Other operating income	233.07	46.55	47.09	432.36	316.12	524.48	454.60
Total income from operations (net)	2,531.97	3,482.19	3,465.38	14,825.66	13,801.80	17,349.63	15,771.60
2 Expenses							
(a) Cost of materials consumed	1,277.19	1,632.57	2,090.31	7,812.36	8,306.20	8,481.73	8,918.13
(b) Purchases of stock-in-trade	27.93	204.78	11.31	447.08	592.86	447.08	592.86
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(557.97)	99.91	(92.29)	(947.61)	512.92	(763.16)	416.29
(d) Employee benefits expense	669.83	584.56	514.21	2,398.05	2,097.60	2,727.35	2,369.63
(e) Depreciation and amortisation expense	142.60	145.62	126.70	574.61	508.02	861.68	766.94
(f) Other expenses (Any item exceeding 10% of the total)	1,029.15	961.33	952.74	4,196.00	4,137.91	4,810.34	4,759.08
Total expenses	2,588.73	3,628.77	3,602.98	14,480.49	16,155.51	16,565.02	17,822.93
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(56.76)	(146.58)	(137.60)	345.17	(2,353.71)	784.61	(2,051.33)
4 Other income	(17.74)	13.02	4.60	323.90	217.82	336.96	294.15
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(74.50)	(133.56)	(133.00)	669.07	(2,135.89)	1,121.57	(1,757.18)
6 Finance costs	366.10	277.66	391.94	1,520.75	1,348.08	1,527.75	1,354.76
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(440.60)	(411.22)	(524.94)	(851.68)	(3,483.97)	(406.18)	(3,111.94)
8 Exceptional items	-	-	-	-	-	-	-
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	(440.60)	(411.22)	(524.94)	(851.68)	(3,483.97)	(406.18)	(3,111.94)
10 Tax expense	(9.76)	(9.73)	(16.57)	(39.06)	(16.57)	(71.06)	(135.14)
11 Net Profit / (Loss) from ordinary activities after tax (9 - 10)	(430.84)	(401.49)	(508.37)	(812.62)	(3,467.40)	(477.24)	(3,247.08)
12 Extraordinary items (net of tax expense Rs. NIL)	-	-	-	-	-	-	-
13 Net Profit / (Loss) for the period (11 + 12)	(430.84)	(401.49)	(508.37)	(812.62)	(3,467.40)	(477.24)	(3,247.08)
14 Share of profit / (loss) of associates	-	-	-	-	-	-	-
15 Minority interest	-	-	-	-	-	-	-
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14 +15)	(430.84)	(401.49)	(508.37)	(812.62)	(3,467.40)	(477.24)	(3,247.08)
17 Paid-up equity share capital- Face Value Rs. 10/- each	805.05	805.05	805.05	805.05	805.05	805.05	805.05
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	3,558.04	4,370.66	4,481.64	5,046.58
19 Earnings per share (before extraordinary items)							
(a) Basic	(5.35)	(4.99)	(6.31)	(10.09)	(43.07)	(5.93)	(40.33)
(b) Diluted	(4.87)	(4.54)	(6.31)	(9.18)	(43.07)	(5.39)	(40.33)
19 Earnings per share (after extraordinary items)							
(a) Basic	(5.35)	(4.99)	(6.31)	(10.09)	(43.07)	(5.93)	(40.33)
(b) Diluted	(4.87)	(4.54)	(6.31)	(9.18)	(43.07)	(5.39)	(40.33)

## PART II

Select Information for the year ended 31/03/2013

Particulars	Quarter ended			Current year ended	Previous year ended	Current year ended	Previous year ended
	(31/03/2013)	(31/12/2012)	(31/03/2012)	(31/03/2013)	(31/03/2012)	(31/03/2013)	(31/03/2012)
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
<b>A PARTICULARS OF SHAREHOLDING</b>							
<b>1 Public shareholding</b>							
- Number of shares	2439685	2439685	2439685	2439685	2439685	2439685	2444029
- Percentage of shareholding	30.30	30.30	30.30	30.30	30.30	30.30	30.36
<b>2 Promoters and Promoter Group Shareholding</b>							
<b>a) Pledged / Encumbered</b>							
- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	
- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL	
<b>b) Non - encumbered</b>							
- Number of shares	5610815	5610815	5610815	5610815	5610815	5610815	
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100	100	
- Percentage of shares (as a % of the total share capital of the company)	69.70	69.70	69.70	69.70	69.70	69.70	

Particulars	3 months ended (31/03/2013)
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed of during the quarter	-
Remaining unresolved at the end of the quarter	-




# THEMIS MEDICARE LTD

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat.  
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

₹ IN LAKHS

Statement of Assets and Liabilities as on 31st Mar, 2013.		STANDALONE		CONSOLIDATED	
	Particulars	As at 31/03/2013	As at 31/03/2012	As at 31/03/2013	As at 31/03/2012
<b>A</b>	<b>EQUITY AND LIABILITIES</b>				
1	Shareholders' Funds				
	(a) Share capital	805.05	805.05	805.05	805.05
	(b) Reserves and surplus	3,558.04	4,370.66	4,481.64	5,046.58
	(c) Amount Received against Share Warrants	85.00	-	85.00	-
	<b>Sub-total - Shareholders' Funds</b>	<b>4,448.09</b>	<b>5,175.71</b>	<b>5,371.69</b>	<b>5,851.63</b>
2	Non-current Liabilities				
	(a) Long-term borrowings	6,045.16	3,543.24	9,201.79	6,491.26
	(b) Deferred tax liabilities (net)	269.93	308.99	516.05	511.72
	(c) Other long-term liabilities	150.50	125.35	150.50	125.35
	(d) Long-term provisions	-	-	30.99	29.73
	<b>Sub-total - Non-current Liabilities</b>	<b>6,465.59</b>	<b>3,977.58</b>	<b>9,899.33</b>	<b>7,158.06</b>
3	Current Liabilities				
	(a) Short-term borrowings	5,054.95	7,535.00	5,054.95	7,535.00
	(b) Trade payables	4,951.30	5,740.06	5,147.33	5,903.30
	(c) Other current liabilities	1,403.31	1,238.46	1,474.91	1,292.88
	(d) Short-term provisions	201.42	159.36	391.91	300.18
	<b>Sub-total - Current liabilities</b>	<b>11,610.98</b>	<b>14,672.88</b>	<b>12,069.10</b>	<b>15,031.36</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>22,524.66</b>	<b>23,826.17</b>	<b>27,340.12</b>	<b>28,041.05</b>
<b>B</b>	<b>ASSETS</b>				
1	Non-current Assets				
	(a) Fixed Assets	10,412.08	11,041.92	13,490.87	14,052.50
	(b) Non-current investments	1,046.28	737.81	359.18	50.71
	(c) Long-term Loans and Advances	772.52	706.03	1,068.48	953.54
	(d) Other non-current assets	27.33	19.27	54.95	44.54
	<b>Sub-total - Non-current assets</b>	<b>12,258.21</b>	<b>12,505.03</b>	<b>14,973.48</b>	<b>15,101.29</b>
2	Current assets				
	(a) Inventories	4,754.57	3,861.25	5,470.63	4,723.02
	(b) Trade Receivables	2,637.55	4,311.55	3,241.34	4,812.67
	(c) Cash and Cash Equivalents	570.29	536.65	1,201.39	669.86
	(d) Short-term Loans and Advances	2,304.04	2,611.69	2,453.28	2,734.21
	<b>Sub-total - Current assets</b>	<b>10,266.45</b>	<b>11,321.14</b>	<b>12,366.64</b>	<b>12,939.76</b>
	<b>TOTAL - ASSETS</b>	<b>22,524.66</b>	<b>23,826.17</b>	<b>27,340.12</b>	<b>28,041.05</b>

**NOTES:**


1. The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
2. The figures of last quarter for the current year are the balancing figures between the audited figures in respect of the full financial year ended 31st March, 2013 and the unaudited published year to date figures upto the third quarter ended 31st December 2012 which were subjected to a limited review.
3. 4 lac fully convertible preferential warrants issued to some of the promoters during the year under review will be converted into Equity Shares on 16.01.2014.
4. The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 15th May, 2013.

As per Review Report attached  
For M. T. Ankleshwaria & Co.  
Chartered Accountants



Madhu T. Ankleshwaria  
Proprietor

By Order of the Board  
For THEMIS MEDICARE LTD



Dr. DINESH PATEL  
(Managing Director & CEO)

Place : Mumbai  
Date : 15 /05 /2013